Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
FiercePharma4d
Regulatory tracker: Agios' Pyrukynd gets updated liver injury warning on its label
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise ...
Big Blue Chip Dividends? Try These ‘Dogs’ Up To 6.8%
The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.
BioSpace6d
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...
GlobalData on MSN6d
UK MHRA approves MSD’s pulmonary arterial hypertension therapy
MSD has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for sotatercept, marketed as ...
Yahoo Finance6d
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).
Pharmabiz5d
Merck Sharp & Dohme’s sotatercept gets UK MHRA marketing approval to treat adult patients with pulmonary arterial hypertension
Merck Sharp & Dohme’s sotatercept gets UK MHRA marketing approval to treat adult patients with pulmonary arterial hypertension: United Kingdom Friday, January 3, 2025, 17:00 Hrs ...
Yahoo Finance6d
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).